| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5873360 | GLAXOSMITHKLINE | Inhalation device |
Feb, 2016
(8 years ago) | |
|
US5873360 (Pediatric) | GLAXOSMITHKLINE | Inhalation device |
Aug, 2016
(7 years ago) | |
Serevent is owned by Glaxosmithkline.
Serevent contains Salmeterol Xinafoate.
Serevent has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Serevent are:
- US5873360
- US5873360*PED
Serevent was authorised for market use on 19 September, 1997.
Serevent is available in powder;inhalation dosage forms.
The generics of Serevent are possible to be released after 23 August, 2016.
Drugs and Companies using SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 19 September, 1997
Treatment: NA
Dosage: POWDER;INHALATION
More Information on Dosage
SEREVENT family patents
